公开(公告)号：US11634773B2

公开(公告)日：2023-04-25

申请号：US16628067

申请日：2018-07-13

Applicant: THE FRANCIS CRICK INSTITUTE LIMITED ,  UNIVERSITY COLLEGE LONDON ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Charles Swanton ,  Nicholas McGranahan ,  Rachel Rosenthal

IPC: C12Q1/6881 ,  C12Q1/6869 ,  A61K39/00 ,  C12Q1/6886 ,  C07K14/74 ,  C07K16/28

Abstract: The present invention relates to a method for determining whether an HLA allele is lost in a tumour in a subject, wherein said method comprises the step of determining the specific copy number of said HLA allele in said tumour. The invention also relates to a method for treating cancer in a subject, comprising targeting a neoantigen which is predicted to be presented by an HLA molecule encoded by an HLA allele which has been determined not to have been lost in a tumour in said subject.

公开(公告)号：US11098121B2

公开(公告)日：2021-08-24

申请号：US15758165

申请日：2016-09-12

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/395 ,  G16B30/00 ,  C07K16/28 ,  G16B40/00 ,  G01N33/574

Abstract: The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.

公开(公告)号：US20200000904A1

公开(公告)日：2020-01-02

申请号：US16565350

申请日：2019-09-09

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/00 ,  C12Q1/6886 ,  C12N5/0783 ,  G01N33/50 ,  G01N33/574

Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.

公开(公告)号：US20200000903A1

公开(公告)日：2020-01-02

申请号：US16565342

申请日：2019-09-09

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/00 ,  C12Q1/6886 ,  C12N5/0783 ,  G01N33/50 ,  G01N33/574

Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.

公开(公告)号：US20180064793A1

公开(公告)日：2018-03-08

申请号：US15569334

申请日：2016-04-27

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas Mcgranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/00 ,  C12Q1/68 ,  C12N5/0783 ,  G01N33/574 ,  G01N33/50

CPC classification number: A61K39/0011 ,  C12N5/0636 ,  C12N2501/505 ,  C12N2502/99 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/505 ,  G01N33/57423 ,  G01N33/5743

Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.

公开(公告)号：US20230158073A1

公开(公告)日：2023-05-25

申请号：US17919135

申请日：2021-04-16

Applicant: Cancer Research Technology Limited

Inventor： Sergio Quezada ,  Karl Peggs ,  Charles Swanton ,  Ehsan Ghorani ,  James Reading ,  Felipe Galvez-Cancino ,  Despoina Karagianni

IPC: A61K35/17 ,  A61K38/17 ,  A61P35/00

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00

Abstract: The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder, wherein the engineered T cell has modulated expression of one or more genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3. Further provided are activity modulators of one or more proteins encoded by genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3 for use in a method of enhancing immunotherapy in a subject having a proliferative disorder. Also provided are related methods of treatment employing the engineered T cell and/or inhibitor.

公开(公告)号：US20210147934A1

公开(公告)日：2021-05-20

申请号：US16628067

申请日：2018-07-13

Applicant: THE FRANCIS CRICK INSTITUTE LIMITED ,  UNIVERSITY COLLEGE LONDON ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Charles Swanton ,  Nicholas McGranahan ,  Rachel Rosenthal

IPC: C12Q1/6881 ,  C12Q1/6886 ,  A61K39/00 ,  C12Q1/6869

Abstract: The present invention relates to a method for determining whether an HLA allele is lost in a tumour in a subject, wherein said method comprises the step of determining the specific copy number of said HLA allele in said tumour. The invention also relates to a method for treating cancer in a subject, comprising targeting a neoantigen which is predicted to be presented by an HLA molecule encoded by an HLA allele which has been determined not to have been lost in a tumour in said subject.

公开(公告)号：US20180251553A1

公开(公告)日：2018-09-06

申请号：US15758165

申请日：2016-09-12

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: C07K16/28 ,  G06F19/22 ,  G06F19/24 ,  G01N33/574

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/574 ,  G01N33/57411 ,  G16B30/00 ,  G16B40/00

Abstract: The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.